DEXIBUPROFEN

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
ATC M01AE14
UNII 671DKG7P5S
EPA CompTox DTXSID9048724

Structure

InChI Key HEFNNWSXXWATRW-JTQLQIEISA-N
Smiles CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
InChI
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H18O2
Molecular Weight 206.28
AlogP 3.07
Hydrogen Bond Acceptor 1.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 37.3
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 15.0

Bioactivity

Mechanism of Action Action Reference
Cyclooxygenase inhibitor INHIBITOR PubMed PubMed
Protein: Cyclooxygenase
Description: Prostaglandin G/H synthase 1
Organism : Homo sapiens
P23219 ENSG00000095303
Protein: Cyclooxygenase
Description: Prostaglandin G/H synthase 2
Organism : Homo sapiens
P35354 ENSG00000073756
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - - 20
Enzyme Oxidoreductase
- 1480-16150 - - 29-90
Enzyme
- 1480-16150 - - 29-90
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Chemokine receptor CXC chemokine receptor
- 100 - - 34
Assay Description Organism Bioactivity Reference
Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear cells Homo sapiens 100.0 nM
Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M Mus musculus 99.0 %
Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M Homo sapiens 34.0 %
Inhibition of Fischer 344 rat brain acetylcholine esterase at 0.6 mM Rattus norvegicus 20.0 %
Inhibition of COX1 by human platelet assay Homo sapiens 90.0 %
Inhibition of LOX12 by human platelet assay Homo sapiens 29.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan induced paw swelling at 70 mg/kg, po after 3 hrs Rattus norvegicus 30.3 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan induced paw swelling at 70 mg/kg, po after 4 hrs Rattus norvegicus 23.9 %
Binding affinity to amyloid beta fibrils None 44.4 nM
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) Homo sapiens 105.0 nM
Inhibition of COX1 in human HEL 92.1.7 cells assessed as thromboxane B2 production incubated for 30 mins before arachidonic acid addition measured after 15 mins by ELISA Homo sapiens 98.65 nM
Inhibition of COX2 in LPS-stimulated and PMA-treated human U937 cells assessed as PGE2 production after 15 mins by ELISA Homo sapiens 730.0 nM
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg, ig administered 1 hr before carrageenan challenge measured after 4 hrs post carrageenan challenge by plethysmometer Rattus norvegicus 29.5 %
Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 30 mg/kg, ig administered 1 hr before acetic acid challenge measured 10 mins post acetic acid challenge Mus musculus 68.7 %
Anti-inflammatory activity in Balb-C Mus musculus (mouse) assessed as inhibition of FCA-induced paw oedema at 0.30 mmol/kg, ip administered 5 min before FCA challenge measured after 3 hr relative to control Mus musculus 53.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 7.67 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 9.369 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.04 %

Related Entries

Cross References

Resources Reference
ChEBI 43415
ChEMBL CHEMBL175
DrugBank DB09213
DrugCentral 3851
FDA SRS 671DKG7P5S
PDB IBP
PharmGKB PA166049174
PubChem 39912
SureChEMBL SCHEMBL43531
ZINC ZINC000000002647
CONTENTS